Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Surgeons Slowed Use of Pelvic Mesh Following FDA Warning, N.Y. Study Shows

This article was originally published in The Gray Sheet

Executive Summary

Use of surgical mesh for pelvic organ prolapse procedures in New York state declined following a 2011 FDA warning, according to a new study.

You may also be interested in...

TOPAS Fecal Incontinence Device Gets Unanimous Support For Approval At FDA Panel

All members of the agency's Gastroenterology and Urology Devices Panel were convinced by Astora Women’s Health's evidence in support of PMA approval for the TOPAS mesh implant device for fecal incontinence.

Regulatory News In Brief

Transvaginal surgical mesh scrutiny

QUOTED. 4 December. Eric Borin.

Becton Dickinson will spend $1.2bn over the next four years to improve its drug-delivery device manufacturing capabilities. See what Eric Borin, president of BD, said about it here.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts